Policy & Regulation
Inotrem signs strategic licensing agreement with Roche for a companion diagnostics test in septic shock
21 January 2020 -

Biotechnology company Inotrem SA announced on Tuesday the extension of a worldwide licensing agreement with Roche Diagnostics for the commercialisation of a mechanism-based companion diagnostic test using a soluble plasma protein (sTREM-1).

Since 2017, the companies are jointly developing an in vitro assay for measurement of sTREM-1 in plasma samples of septic shock patients. Measurement of sTREM-1 in blood provides a valuable indicator for the severity and outcome prediction of septic shock patients.

The incidence of septic shock continuously raises and mortality remains elevated (35%) in developed countries. There is currently no specific mechanism-based therapy approved for this indication besides antibiotics and symptomatic treatment.

In addition, Inotrem's therapeutic solution has the potential to become the first targeted treatment for septic shock. The companion diagnostic test will allow a stratification of patients to identify those who are more likely to respond to its treatment.

Recently, Inotrem said it enrolled its first septic shock patient under its Phase IIb study in the ASTONISH trial. The study aims at demonstrating efficacy of its lead compound, nangibotide and bring a clinically relevant proof of clinical activity in septic shock patients. It intends to confirm the value of soluble TREM-1 as potential companion diagnostic test to identify patients likely to benefit from nangibotide treatment.